|
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 64.16% | Shs Outstand | 11.63M | Perf Week | -34.44% |
| Market Cap | 29.90M | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 3.55M | Perf Month | - |
| Income | - | PEG | - | EPS next Q | - | Inst Own | - | Short Float / Ratio | - / - | Perf Quarter | - |
| Sales | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Interest | - | Perf Half Y | - |
| Book/sh | -0.14 | P/B | - | EPS next Y | - | ROA | - | Target Price | - | Perf Year | - |
| Cash/sh | - | P/C | - | EPS next 5Y | - | ROE | - | 52W Range | 2.60 - 6.75 | Perf YTD | -37.62% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -61.93% | Beta | - |
| Dividend % | - | Quick Ratio | - | Sales past 5Y | - | Gross Margin | - | 52W Low | -1.15% | ATR | 1.04 |
| Employees | 1 | Current Ratio | - | Sales Q/Q | - | Oper. Margin | - | RSI (14) | - | Volatility | 11.82% - |
| Optionable | No | Debt/Eq | - | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.07 | Prev Close | 2.62 |
| Shortable | Yes | LT Debt/Eq | - | Earnings | - | Payout | - | Avg Volume | 1.80M | Price | 2.57 |
| Recom | - | SMA20 | -21.33% | SMA50 | -21.33% | SMA200 | -21.33% | Volume | 118,449 | Change | -1.91% |
 | ||||||||||
| ||||||||||
|
||||||||||
| ||||||||||
| Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. | ||||||||||
| ||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite